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Abstract: This review focuses on the treatment of attention deﬁ  cit hyperactivity disorder 
(ADHD) in adults. It brieﬂ  y addresses prevalence, diagnostic and differential diagnostic issues 
speciﬁ  c to adults. Stimulant medication, non-stimulant medication, and psychosocial treatments 
are thoroughly reviewed. For each class of medication possible mechanism of action, efﬁ  cacy 
and side effects are summarized. Special attention is given to the pharmacological treatment 
for patients with adult ADHD and various comorbidities. In summary, stimulant medications 
are most effective and combined medication and psychosocial treatment is the most beneﬁ  cial 
treatment option for most adult patients with ADHD.
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Introduction
Attention deﬁ  cit hyperactivity disorder (ADHD) is one of the most common develop-
mental disorders (Spencer et al 2007). It is estimated to affect 5%–10% of the child 
population (Faraone et al 2003) and from 1%–6% of the adult population (Kessler et al 
2005). In a recent large epidemiological study in the United States, 4.4% of the adult 
population was determined to have clinically signiﬁ  cant ADHD symptoms (Kessler 
et al 2006). ADHD is, therefore, a very prevalent disorder across the developmental 
spectrum.
Nature of the impairment
ADHD was considered for many years to be a disorder limited to childhood due to 
diminishing externalizing behaviors. However, as longitudinal studies have demon-
strated, the symptoms remain clinically signiﬁ  cant for the majority of ADHD patients 
well into adulthood (Weiss and Hechtman 1993). Recent evidence suggests that almost 
sixty-six percent of individuals diagnosed as children with ADHD, report at least one 
ADHD symptom causing clinically signiﬁ  cant impairment during adulthood (Weiss 
et al 2002).
ADHD is characterized by behavioral and cognitive symptoms such as hyperac-
tivity, inattention, disorganization, and impulsivity. The symptoms must be severe 
and cause clinically signiﬁ  cant impairment persistently in multiple domains of an 
individual’s life in order to warrant a diagnosis. In childhood, the most problematic 
symptoms are hyperactivity, impulsivity, and inattention. These problems result in 
disruptive behavior at home and at school, which frequently initiates clinical referral 
for diagnosis and treatment. In adulthood the hyperactivity decreases but inattention, 
disorganization, and impulsivity result in difﬁ  culty functioning both at home and at 
work. The predominant complaints seen in adult patients are trouble organizing and 
completing necessary tasks related to either higher education or employment. Adult 
patients with ADHD have higher rates of academic failures and transfers, lower 
incomes, higher rates of job loss and turnover, high rates of car accidents, and increased Neuropsychiatric Disease and Treatment 2008:4(2) 390
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rates of divorce (Spencer et al 2007). It is also reported that 
adults with ADHD have a higher prevalence of anxiety, 
depression (Kessler et al 2006), drug abuse, and antisocial 
behaviors (Barkley et al 2004) than the general population.
Diagnosis
Diagnosing of ADHD for the ﬁ  rst time in adulthood is 
complex. A childhood diagnosis or childhood symptoms 
compatible with an ADHD diagnosis are required for an 
adult diagnosis. However, such a history may not be present 
in very bright individuals, and/or people who had primarily 
inattentive subtypes of ADHD, because in these individuals 
impairment may only become signiﬁ  cant when structure and 
supports decrease and demands increase.
According to the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) Text Revision (DSM–IV TR) 
(American Psychological Association 2000) diagnostic 
criterion, the symptoms must have started prior to age 7, be 
age inappropriate, cause impairment in multiple domains and 
not be caused by other conditions. The DSM-IV TR ADHD 
diagnosis is broken down into three subgroups: ADHD 
predominately inattentive; ADHD predominately hyperac-
tive-impulsive; and ADHD combined type. In order for an 
adult to receive a diagnosis, the adult must have 6 of the 9 
listed DSM-IV symptoms in at least one subtype and these 
symptoms must have caused consistent clinically signiﬁ  cant 
impairment for 6 months or more (American Psychiatric 
Association 2000).
There are four important limitations in using the DSM-
IV to diagnose adults with ADHD. The ﬁ  rst is that criteria 
were determined in ﬁ  eld trials of children, and as is typical 
the criterions were set at the 93rd percentile suggesting the 
top 7% would receive the diagnosis. However when the 
same cut offs are used in adults with ADHD the cut offs fall 
around the 99th percentile. Therefore, the cut offs may not be 
appropriate for this population and in fact some physicians 
advocate that 5 of the 9 symptoms are a sufﬁ  cient number 
of symptoms for adult patients (Barkley 1990). The second 
limitation is that the listed hyperactive symptoms are not 
developmentally appropriate for adults. The third limitation 
is that childhood symptoms are sometimes difﬁ  cult for adult 
patients to recall and there may not be a parent or older sibling 
who can validate the syndrome starting prior to age 7. When 
diagnosing adult ADHD, it may be appropriate to change 
the required age onset to 12. The fourth problem with the 
DSM-IV TR is measuring clinically signiﬁ  cant impairment 
is difﬁ  cult for both children and adults, but more so for adults 
who have complex and different life demands.
Scales, measures, and semi-structured clinical interviews 
can be efﬁ  cient means of garnering information to help 
establish an adult ADHD diagnosis. Scales should not be used 
exclusively to establish a diagnosis because many psychiatric 
disorders have features of ADHD. Additionally, most adults 
experience some of the symptoms of ADHD, such as for-
getfulness or disorganization, from time to time, but these 
symptoms are not consistent with an ADHD diagnosis in 
most individuals. A trained clinician with the intricate under-
standing of clinical impairments and the nature of ADHD 
can use scales and interviews to guide diagnosis.
Differential diagnosis
Psychiatric disorders
Many psychiatric disorders exist that can mimic the symp-
toms of ADHD in both child and adult populations. The 
psychiatric disorders that mimic ADHD symptoms include 
anxiety disorders, mood disorders, adjustment disorders, 
learning and language deﬁ  cits, and some psychotic disorders. 
In addition, it is important to note that individuals dealing 
with high levels of stress may exhibit the symptoms of 
ADHD. The presence and severity of possible alternative 
explanations for patients’ symptoms need to be evaluated 
carefully in order to ensure that the diagnosis is accurate and 
treatment options can be weighted appropriately.
Medical disorders
A thorough medical history can be useful to help guide 
diagnosis since many medical conditions can present with 
symptoms similar to ADHD. Patients with histories of any 
one of the following should be more carefully evaluated and 
referred for other evaluations and possibly other treatments 
as is necessary: developmental disorders, seizure disorders 
(petit mal), sleep apnea, hearing and vision problems, thyroid 
disorders, lead poisoning, and hypoglycemia. Additionally, 
patients currently taking any medications or with histories of 
severe drug or alcohol abuse need to be evaluated and treated 
carefully, since the consumption of some medications and 
drugs can cause ADHD-like symptoms.
While there are speciﬁ  c symptoms that can help to guide 
differential diagnosis, this matter is not entirely straight 
forward since individuals with ADHD are often comorbid 
with other illnesses. Thus, if a patient is suffering with severe 
symptoms of other disorders, such as anxiety or depression, we 
ﬁ  rst attempt to address the most severely impairing disorder to 
determine whether the ADHD symptoms improve. If a patient 
displays moderate symptoms of other psychiatric disorders, it 
is often a matter of clinical judgment as to how to proceed.Neuropsychiatric Disease and Treatment 2008:4(2) 391
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It is very common that adults with ADHD have 
comorbidities. In a recent large-scale family study 81% of 
adults with ADHD had at least one comorbid diagnosis, while 
56% had at least two comorbid diagnoses (McGough et al 
2005). The most common disorders encountered with adult 
ADHD patients are: substance abuse and d15ependence, 
mood disorders, anxiety disorders, and personality disorders 
such as antisocial personality disorder and borderline per-
sonality disorder. Multiple studies have demonstrated that 
up to 50% of adult patients with ADHD have had comorbid 
substance use problem (Sobanski 2006). Retrospective stud-
ies of adults with ADHD have demonstrated that 30%–50% 
have had one or more episodes of depression, while 40%–
60% have had an anxiety disorder throughout their lifespan 
(Sobanski 2006). Personality disorders and speciﬁ  cally 
antisocial personality disorder, are seen at increased rates in 
adults with ADHD (Mannuzza et al 1998). In instances of 
comorbidity, treatment can be more complex.
Treatment
Treatment of adults with ADHD consists of medication and 
psychosocial treatment. Each treatment modality addresses 
particular problems of ADHD patients. The treatments can 
be administered separately or as is most common, both types 
of treatments can be combined.
Pharmacological treatment
for adult ADHD
ADHD medications are roughly divided into stimulants 
and non-stimulant medication. Long-acting stimulant 
preparations are recommended as they result in better patient 
compliance and longer-lasting, smoother improvement of 
symptoms.
Stimulant medication
Stimulants include methylphenidate and amphetamine 
compounds. Stimulants are the most effective medications 
for the treatment of ADHD, with responsiveness rates in the 
70%–80% range (Spencer et al 2005).
Mechanism of action
Our understanding of the mechanism of action of stimulant 
medications is undergoing constant revision. Although the 
exact mechanism of action is unknown, these agents are 
thought to block reuptake of norepinephrine and dopamine 
into the presynaptic neuron, thereby increasing extraneuronal 
catecholamines (Fone and Nutt 2005; Arnsten 2006). Nor-
epinephrine is predominantly connected with frontocortical 
activity, whereas dopaminergic activity is associated with the 
lower striatal structures. Both stimulants bind the dopamine 
transporter protein outside of the cell membrane and block 
dopamine reuptake presynaptically, thus increasing synap-
tic dopamine (Wilens 2006). It has been demonstrated that 
striatal dopamine transporter availability in adult patients 
with ADHD is markedly reduced by methylphenidate, 
even at a low dose (Krause et al 2000). Besides dopamine 
reupatke inhibition amphetamine also increases the release 
of dopamine from presynaptic cytoplasmic storage vesicles 
and blocks the uptake of dopamine into neuronal cytoplasmic 
vesicles, making dopamine more available in the presynaptic 
neuron (Connor 2005). Methylphenidate in low doses, also 
enhances hippocampal norepinephrine efﬂ  ux but does not 
seem to affect dopamine in the nucleus accumbens. The 
data are consistent with the hypothesis that enhanced nor-
adrenergic neurotransmission, particularly in the prefrontal 
cortex, contributes to the effects of methylphenidate (Fone 
and Nutt 2005).
Clinical effects of stimulants
Stimulants have shown a high behavioral efﬁ  cacy in numer-
ous randomized controlled trials conducted since the 1960s, 
with improvement noted for 65%–75% of patients in all age 
groups (Pliszka 2006). Stimulants effectively alleviate the 
symptoms of ADHD, including poor attention span, distract-
ibility, impulsive behavior, hyperactivity, and restlessness. 
Stimulants also improve vigilance, cognition, reaction time, 
response inhibition, and short-term memory (Connor 2005; 
Hechtman 2005). Methylphenidate in clinical doses improves 
spatial working memory, set-shifting, and other prefrontal 
cortex cognitive functions in healthy individuals and in 
children with ADHD (Arnsten and Dadly 2005). Stimulant 
medications are also associated with fewer errors on a driv-
ing simulator in teens and adults with ADHD. Barkley and 
colleagues demonstrated that methylphenidate may have a 
beneﬁ  cial effect on some aspects of driving, for example 
less steering variability, slower driving speed, greater use 
of turn signals, and a fewer impulsive responses (Barkley 
et al 2005).
Side effects
Side effects of stimulants are dose-dependent, are gener-
ally mild to moderate in most patients, and can be managed 
either by decreasing the dose or changing the time when 
medication is given (Weiss and Hechtman 1993). Common 
adverse effects of stimulants include insomnia, anorexia, 
nausea, decreased appetite, weight loss, headache, increased Neuropsychiatric Disease and Treatment 2008:4(2) 392
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blood pressure, elevated pulse, abdominal pain, irritability, 
and mood lability. Stimulants may also cause tics, which is a 
frequent reason for discontinuing the stimulant medication in 
children. In rare cases stimulants may cause seizures, hyper-
tension, psychosis, hepatotoxicity, and in children stimulant 
may effect growth (Power 2000; Greenhill 2001). Many side 
effects emerge early in the course of therapy with stimulants 
and decline in intensity over time. Side effects, such as 
irritability, developing late in the day may present rebound 
phenomena and in this case giving a small supplemental dose 
of stimulant in the afternoon may be helpful.
Initial insomnia is a relatively common side effect of 
stimulants. However, it is important to make sure to dif-
ferentiate whether insomnia is a side effect of stimulants 
or predates treatment. Insomnia as a side effect can be 
minimized by avoiding doses in the afternoon and evening 
and by establishing good sleep routines and schedules. In 
the treatment with short-acting methylphenidate or amphet-
amine, insomnia may be secondary to a behavioral rebound 
that occurs with the wearing off of the stimulant’s effects on 
ADHD symptoms (Powers 2000).
Treatment with all stimulants is associated with a mild 
increase in blood pressure and pulse. Generally, this slight 
increase is not clinically signiﬁ  cant. However, for adults 
with borderline hypertension and those with antecedent 
cardiac disease, it could be clinically signiﬁ  cant. What to 
do with patients with borderline hypertension has remained 
a clinical dilemma. Results of a recent open-label study in 
adults with ADHD who had a history of treated hypertension 
or manifest hypertension demonstrated that treatment with 
mixed amphetamine salt XR did not produce a clinically 
signiﬁ  cant increase of blood pressure and hypertension dur-
ing the treatment (Wilens et al 2006).
Mood lability may be a result of ADHD rebound symp-
tom or adverse effect of stimulants. If it is a side effect of 
stimulants, switching to another stimulant (such as methyl-
phenidate or amphetamine) or switching to non-stimulant 
medication may be warranted. Sometimes, combination 
therapy with antidepressants may be useful (Weiss et al 
1999).
Very rare adverse events can include psychotic symp-
toms, manic symptoms, aggression, and suicidality. Rarely 
reports of psychotic symptoms demonstrated visual and 
tactile hallucinations of insects (Pliszka 2007).
Contraindications for stimulant treatment are: ﬂ  orid 
psychosis, bipolar I disorder, Tourette’s disorder, severe 
anorexia, and some medical condition such as hypertension, 
tachycardia, and arrhytmias (Greenhill 2001).
Methylphenidate
Methylphenidate (MPH) is a stimulant that has been 
clinically available for 50 years, and its efﬁ  cacy and safety 
have been thoroughly studied. It is administered orally 
with a starting dose of 10 mg for adults. The recommended 
dose is 0.3–1.5 mg/kg/day (Fawcet 2005) and maximum 
dose for adults ranges from 80 to 108 mg a day. The higher 
doses of MPH lead to better therapeutic response (Faraone 
et al 2004).
MPH is rapidly and extensively absorbed after oral 
administration. After absorption, it undergoes extensive 
ﬁ  rst-pass hepatic metabolism, predominantly by hydrolysis. 
Eighty percent of the drug is excreted as ritalinic acid, and the 
remainder is oxidized by a hepatic mixed-function oxidase 
(Connor 2005).
There are three pharmaceutical formulations of methyl-
phenidate – (1) immediate release or short-acting formulation 
(brand name Ritalin), (2) sustained release or intermedi-
ate-acting methylphenidate (brand name Ritalin SR), and 
(3) extended release or long-acting methylphenidate (brand 
names Concerta, Biphentin, Ritalin LA). The release mecha-
nism of the intermediate-acting methylphenidate (Ritalin 
SR) produces variable results making this preparation less 
useful.
The main advantage of short-acting MPH products is 
their usefulness in situations where a supplement to the once 
daily medication is required or if the patient desires more 
ﬂ  exibility over the dosing schedule (CADDRA 2006). The 
titration schedule is presented later in the paper.
The rates of MPH abuse are minimal compared to 
those of cocaine and D-amphetamine (Kollins et al 2001). 
Methylphenidate is most commonly administered orally, 
which limits its abuse liability compared to the injected or 
insufﬂ  ated forms of other stimulants. However, it can be 
dissolved and injected and, therefore, there is some concern 
about abuse and diversion of short-acting methylphenidate 
(Kollins et al 2001).
Clinical trials on short-acting and long-acting MPH 
formulations are stated in Table 1. Results of these studies 
have demonstrated that all MPH formulations are safe and 
effective in the tretment of ADHD symptoms in adults.
Controlled released methylphenidate (Biphentin) has a 
unique multi-layer release delivery system with a duration 
of action of 10–12 hours. The capsule is composed of beads. 
Each bead has two layers where the outside coat provides 
immediate release of methylphenidate (40% of the total 
dose) and then the controlled release layer provides 60% of 
the total dose.Neuropsychiatric Disease and Treatment 2008:4(2) 393
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The initial dose is 10 mg (CADDRA 2006). Controlled 
released MPH is available in seven different dosages, and the 
capsule can be opened so that the drug may be sprinkled on 
food. It is approved for the treatment of ADHD in children, 
adolescents, and adults. Results of a randomized, multi-
center, double-blind, placebo-controlled, crossover study in 
39 adults with ADHD demonstrated signiﬁ  cant behavioral 
improvement in those who received controlled released MPH 
compared with those who received the placebo. The treat-
ment was well tolerated, and there were no serious adverse 
events (Jain et al 2007).
OROS methylphenidate (Concerta) is an extended release 
MPH, that uses an oral osmotic release system (OROS). Clin-
ical trials have shown OROS MPH to have continued action 
throughout a 10–12-hour period. The capsule has two drug 
compartments and a water absorption compartment. Water is 
absorbed and pushes the medication out through a lazer hole 
at the end of the capsule. Twenty-two percent of the drug 
is coated on the outside of the capsule and is immediately 
available. The MPH that is released from the ﬁ  rst medication 
compartment is supposed to provide sufﬁ  cient improvement 
of symptoms in the morning. If it is not sufﬁ  cient, a small 
dose of short-acting MPH may also be added in the morning 
(CADDRA 2006). The medication is not ofﬁ  cially approved 
for adults, but at times it is used for this population because 
of its long duration and once daily administration. However, 
it is only available in four dosages (18, 27, 36, and 54 mg) 
and adults may require up to 108 mg, thus doubling the cost 
when two tablets are needed.
An important advantage of OROS-MPH is that it is asso-
ciated with less risk of diversion and abuse than the immedi-
ate release preparations. Whereas immediate release MPH 
Table 1 Clinical trials on stimulant medication in adults with ADHD
Stimulants’ study  N  Method  Outcome  Conclusion
Short-acting 
stimulants
MPH* 23  Duble-blind  ADHD  symptoms  ↓  MPH is signiﬁ  cantly
(Spencer    crossover study  (78%)  more effective than
et al 1995)        placebo
MPH 146  Duble-blind  ADHD  symptoms  ↓  MPH is signiﬁ  cantly
(Spencer    randomized  (76%)  more effective than 
et al 2005)    study  No serious CV  placebo
     adverse  events  Good  tolerability
Long-acting 
stimulants
Controlled release  39  Double-blind  ADHD symptoms ↓ Successful  in
MPH    placebo-controlled  Weight loss  symptoms control
 /Biphentin/    crossover study    Well tolerated 
(Jain et al 2007)
OROS-MPH  32  Uncontrolled, open  ADHD symptoms ↓  Successful control
/Concerta/    label study  Functional  of symptoms
(Fallu et al 2006)      improvements  Less functional
     (Sheehan  scale)  disability
OROS-MPH 141  Double-blind,  ADHD  symptoms  ↓ Successful  control 
/Concerta/   randomized,  ↑Systolic and  of symptoms
(Biederman    placebo controlled  diastolic blood  Concerns about CV
et al 2006)    study  pressure and heart  tolerability 
     rate
OROS-MPH 47  Double-blind,  ADHD  symptoms  ↓ Less  remarkable
/Concerta/   placebo-controlled,  (41%–42%  symptoms  improvement
(Reimherr    crossover study  reduction)  than in other
et al 2007)        comparable 
       studies
Mixed amphetamine  223  Double-blind,  ADHD symptoms ↓ Sustained
salts XR    placebo-controlled  (sustained impro-  symptomatic
/Adderall XR/    study  vement up to 24  impovement
(Biederman et al 2005)      months)  Well tolerated
      Good tolerance  
*MPH – methylphenidateNeuropsychiatric Disease and Treatment 2008:4(2) 394
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can be crushed and parenterally administered as a common 
way of abuse, the OROS delivery mechanism does not allow 
the pills to be crushed and injected or inhaled. Moreover, the 
gradual enhancement of the concentration of MPH within 
the OROS formulation leads to a slower onset of the block-
ade of presynaptic dopamine transporter and, thus, to a less 
detectable feeling of euphoria (Kollins et al 2001; CADDRA 
2005; Biederman et al 2006).
Clinical trials have demonstrated that OROS-MPH is well 
tolerated and signiﬁ  cantly more effective than a placebo in 
of treating core ADHD symptoms and improving executive 
functions (Biederman et al 2006; Fallu et al 2006).
The proﬁ  le of its side effects is similar to those of immedi-
ate released MPH. With regard to cardiovascular side effects, 
only a few patients in this study had systolic blood pressure 
above 140 mmHg and pulse above 114 bpm (Biederman et al 
2006). Adults with borderline hypertension should be care-
fully monitored in terms of cardiovascular parameters.
Methylphenidate transdermal system is a MPH patch 
that delivers continuous medication release throughout 
the day. Clinical trials in children with ADHD have dem-
onstrated that MPH transdermal system is generally well 
tolerated with mild to moderate side effects (Biederman 
2006). This treatment option has been approved by the FDA 
in the United States and approval is being sought in other 
countries. There are no clinical trials demonstrating the 
efﬁ  cacy of methylphenidate transdermal delivery system 
in adults with ADHD.
Dextroamphetamine
Dextroamphetamine is a common used stimulants, which 
has been available and studied for many decades. Currently, 
there are three different formulations regarding the duration 
of action: (1) Immediate-release dextroamphetamine (Dex-
edrine), (2) Sustained-release dextroamphetamine (Dexedrine 
spansule), and (3) Extended-release mixed amphetamine salts 
(Adderell XR). Dextroamphetamine immediate-release has 
a short half-life of 4–6 hours and requires multiple dosages 
two or three times a day. Therefore, it may be considered a 
second-line agent for adults with ADHD. It is recommended 
in situations where supplement to the once daily medication 
is required or if the patients request more ﬂ  exibility over 
the dosing schedule (CADDRA 2006). Starting dose for 
dextroamphetamine is 5 mg and recommended doses are 
0.3–1.5 mg/kg with a maximum of 60 mg a day for adults 
(Wilens et al 2002). After oral administration dextroamphet-
amine is quickly adsorbed. About a half of a given dose is 
eliminated unchanged in the urine, while the other half is 
broken down into various metabolites, mostly benzoic acid 
(Powers 2000).
Clinical trials on amphetamine compunds are described 
in the Table 1. Results of these studies have showed that all 
preparations are safe and effective in the tretment of ADHD 
symptoms in adults.
Dextroamphetamine sustained release (Dexedrine 
spansules) releases the active drug substance in a more 
gradual fashion than the standard formulation. A spansule 
is a capsule in which part of dose is released promptly, 
and remaining of dose is released gradually. Thus, its 
duration of action is a little bit longer, lasting about 6–8 
hours (CADDRA 2006). Therefore, the dextroamphetamine 
sustained release may be given once daily. However, 
similar to short-acting formulations, dextroamphetamine 
sustained release is also considered as a second line agent 
for treatment of ADHD because their duration of action is 
shorter than that of long-acting formulations. However, in 
one child study which compared the efﬁ  cacy of immediate-
release and extended-release amphetamine formulations, 
dextroamphetamine sustained release were signiﬁ  cantly 
more effective at controlling ADHD symptoms than short-
acting formulations during the afternoon and in the early 
evening (James et al 2001).
Unfortunately, there are a few studies which evaluate the 
efﬁ  cacy of dextroamphetamine sustained release in adults 
with ADHD.
Mixed amphetamine salts extended 
release (Adderall XR)
This formulation includes neutral salts consisting of 75% 
dextroamphetamine and 25% levoamphetamine, and it comes 
in a capsule with long and short-acting beads (James et al 
2001). An important advantage of extended released mixed 
amphetamine salts is its extended duration of action. This 
stimulant formulation covers patients for a period from 10–12 
hours. Mixed amphetamine salts XR is available in 6 dosages 
(5, 10, 15, 20, 25 and 30 mg). Fifty percent of the dose is 
immediately available resulting in signiﬁ  cant improvement 
in symptoms in the morning without need for augmentation 
(CADDRA 2006).
Mixed amphetamine salts XR has a good cardiovascular 
tolerability and may be administered in patients with a mild 
hypertension who are on stable antihypertensive medication 
(Wilens et al 2006).
The most common side effects are insomnia, decreased 
appetite and weight loss, headache, dry mouth, and nervous-
ness (Biederman et al 2005).Neuropsychiatric Disease and Treatment 2008:4(2) 395
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Clinical use of stimulants
Choice of medication
Clinical efﬁ  cacy of methylphenidate and dextroamphetamine 
is similar with minor variation between these two drugs. 
Most patients will respond to both drugs. However, 
36% of patients respond preferentially to amphetamine 
compounds while 26% of patients respond preferentially 
to methylphenidate compounds. Some 10% do not respond 
to either one (Greenhill et al 1996). Dextroamphetamine 
has a little longer duration of action (4–5 hours) than 
methylphenidate (3–4 hours) after oral administration of 
short-acting formulations of these drugs. The adverse events 
of both drugs are also similar. However, despite their similar 
levels of efﬁ  cacy, some patients have a better response to 
methylphenidate, while other patients respond better to 
dextroamphetamine. Therefore, stimulant selection needs 
to be very individualized.
Nowadays long-acting stimulants are the standards of 
care. Research about medication satisfaction showed that 
between 40% and 50% of participants reported that they were 
satisﬁ  ed with their short-acting medication, while 70% of 
patients reported satisfaction with their long-acting medica-
tion (Weiss et al 2006). Long-acting stimulant medication 
has advantage over short-acting medication, because patients 
with ADHD are likely to forget to take medications three 
or four times a day. Also they are not usually aware of the 
functional impairment they experience when the effect of the 
short-acting stimulants decreases as a result of missing doses. 
Even in patients who are relatively compliant the burden 
of taking a medication three or four times a day becomes 
unsustainable over time. Therefore, long-acting stimulants 
are the ﬁ  rst-line treatment for adult ADHD patients.
Titration of doses
If short-acting methylphenidate or dextroamphetamine is 
used, the starting dose is 10 mg for methylphenidate or 5 mg 
for dextroamphetamine (see Table 2). This dose should be 
titrated upward for 10 mg or 5 mg every 7 days until the 
optimal beneﬁ  t or until side effects prevent increases. If 
no beneﬁ  ts are noted, switching to the other stimulant is 
indicated.
If long-acting stimulant preparations are used, starting 
dose for extend released MPH (Concerta) is 18 mg, for the 
controlled released MPH (Biphentin) is 10 mg, and 5 mg 
for mixed amphetamine salts XR (Adderall XR). Titration 
schedule is similar for all formulations and every 7 days 
they can be increased up to their maximum doses, which are 
outlined in the Table 2 (CADDRA 2006).
Stimulants show great inter-individual variability in 
terms of response to particular dose. Accordingly, it is very 
important not to titrate too quickly patients who are sensi-
tive (slow metabolizers) or keep those who require higher 
doses on insufﬁ  cient doses (rapid metabolizers). In treatment 
of adult patients with ADHD recommended doses may not 
be adequate. Therefore, thorough titration with accurate 
registration of response to drug as well as side effects is 
very important.
Clinical monitoring during 
stimulant treatment
Once an effective and well-tolerated dose of stimulant 
medications is achieved, routine clinical monitoring 
is needed. Regular clinical monitoring with monthly 
appointments in the beginning of treatment and after 
that clinical monitoring at least every three months has a 
great importance in terms of dose adjustments based on 
residual symptoms and tolerability. During these visits, 
ADHD symptoms, comorbid conditions, side effects of 
medication, heart rate, blood pressure, and weight should 
be monitored, as well as patient’s compliance. The ﬁ  ndings 
of the MTA study strongly suggest that active and intensive 
monitoring of medication improves treatment outcome 
(MTA Cooperative Group 1999). Many patients are prone 
to stop taking medication when they do not have regular 
follow-up appointment.
It is recommended that a reassessment with a trial 
off medication occurs once a year to assess the need for 
medication and appropriateness of the dose (Weiss et al 
1999). Planned drug holidays may also be helpful in 
preventing tolerance to the medication.
Nonstimulant medication
Stimulant medications control ADHD symptoms well in most 
patients with ADHD. However, 10%–30% of patients do not 
respond adequately to stimulant treatment or have intolerable 
side effects (Spencer et al 2004). In such cases nonstimulant 
medications are the next best treatment option for patients 
with ADHD. Nonstimulant options for adults with ADHD 
primarily include atomoxetine and at times bupropion and 
tricyclic antidepressants. Nonstimulant medications are gen-
erally less effective in treating ADHD than stimulants.
Atomoxetine
Atomoxetine is a non-stimulant drug that has shown efﬁ  cacy 
in ADHD patients. Atomoxetine is a selective inhibitor of the 
presynaptic norepinephrine transporter (Wilens 2006), and it Neuropsychiatric Disease and Treatment 2008:4(2) 396
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is approved by the FDA for treatment of ADHD in children 
and adults in the United States.
The onset of action is slower than with stimulants and 
the maximum treatment effect may not be reached for sev-
eral weeks. Atomoxetine is indicated for patients for whom 
stimulants are contraindicated, for patients with substance 
use disorders, for patients with tic disorders, or for those who 
experience severe side effects with stimulant medications.
Atomoxetine does not have an abuse potential, which is an 
important advantage for those adults with ADHD who are at 
risk for substance abuse (Weiss and Weiss 2004; Hechtman 
2005; CADDRA 2006). Other advantages of atomoxetine are 
its once daily dosage, less rebound, and a mild anti-anxiety 
effect, which may be helpful for management of comorbid-
ity (Weiss&Weiss 2004). Starting dose for atomoxetine is 
0.5 mg/kg/day . Dose should be increasing after 14 days to 
0.8 mg/kg/day and then after another 14 days to 1.2 mg/kg/day. 
Maximum dose is less than 100 mg/day (CADDRA 2006).
Since atomoxetine is predominantly metabolized by 
CYP2D6 isoenzyme, caution is indicated for patients who 
are poor metabolizers of CYP2D6 substrates (eg, 7%–10% 
of the population). The slow titration will detect these slow 
metabolizers who will show signiﬁ  cant effects at very low 
dosages (Hechtman 2005). Patients who take medications, 
which inhibit CYP 2D6, such as paroxetine and ﬂ  uoxetine 
may also show signiﬁ  cant effects on small dosages (Belle 
et al 2002; Hechtman 2005). This issue may be important 
for patients with ADHD who have comorbid depression and 
take SSRIs.
The most common side effects of atomoxetine are nau-
sea, decreased appetite (in 15%–20% of patients), insomnia, 
slightly increased diastolic blood pressure and heart rate, 
decreased libido, sweating, and dysuria (Weiss and Weiss 
2004). There is no evidence of other cardiovascular irregu-
larities in atomoxetine treated patients (CADDRA 2006).
The largest studies on evaluation of the efﬁ  cacy and 
safety of atomoxetine were two identical randomized, 
double blind, placebo-controlled multisite studies, which 
included 536 adults with ADHD. Results of these studies 
demonstrated that atomoxetine was superior to placebo in 
reducing ADHD symptoms. Signiﬁ  cant improvement was 
noted in both studies by the second week, and there were no 
serious safety concerns during the treatment. Signiﬁ  cant side 
effects were dry mouth, insomnia, decreased appetite, erectile 
dysfunction, sweating, constipation, and nausea (Michelson 
et al 2003; Spencer et al 2006).
Table 2 Most common medication treatment options for adult ADHD
First line  Duration   Start dose  Titration  Maximum
agents of  action    schedule  dose 
OROS   12 h  18 mg qama  ↑18 mg every 7  
Methylphenidate HCL      days  108 mg/day
(Concerta)     
Long-acting MPH  8–12  10 mg qam  ↑10 mg every 7  
(Ritalin LA)      days  80 mg/day
Controlled release   10–12 h  10 mg qam   ↑10 mg every 7  
Methylphenidate       days  80 mg/day
(Biphentin)     
Mixed Amphetamine   12 h  5 mg qam  ↑ 5 mg every 7  
salts XR      days  60 mg/day
(Adderall XRc)     
Atomoxetine  24 h  0.5 mg/kg/day  ↑ 0.8 mg/kg/day 
(Strattera)      for 10 days, then   100 mg/day
     1.2  mg/kg/day 
Second line agents      
Methylphenidate HCL  3–5 h  10 mg qam   ↑10 mg every 7  
(Ritalin)   and  qnoonb days  100  mg/day
Dextroamphetamine  4–5 h  5 mg qam   ↑ 5 mg every 7  
(Dexedrine)    and qnoon  days  60 mg/day
Dextroamphetamine  6–8 h  10 mg qam  ↑ 5 mg every 7  
Spansule     days  60  mg/day
(Dexedrine spansule)
Source: (CADDRA 2006; Paykina and Greenhill 2007).
aqam – every morning.
bqnoon – at noon.
cAdderall XR – Adderall extended release.Neuropsychiatric Disease and Treatment 2008:4(2) 397
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Bupropion
Bupropion is an antidepressant that may be effective in 
children and adults with ADHD. Precise mechanism of action 
of bupropion is still unclear. Preclinical data and clinical 
research indicate that bupropion is an inhibitor of dopamine 
and norepinephrine reuptake (Fava et al 2005; Wilens 2006). 
Bupropion is metabolized mainly by CYP 2B6, and thus may 
cause clinically important interaction for patients treated 
with SSRIs, especially with ﬂ  uoxetine. Starting dose is usu-
ally 150 mg per day, and maximum daily dosage is 450 mg 
per day (Fava et al 2005). Canadian guidelines for ADHD 
recommend lower doses. The starting dose is 100 mg, and 
maximum dose is 300 mg (CADDRA 2006).
Bupropion is a second-line agent for uncomplicated 
ADHD and possibly a ﬁ  rst-line agent in patients with 
comorbid substance use disorders and mood disorders. 
Bupropion is very useful for treating of patients with bipolar 
disorder because bupropion-treated patients appeared less 
likely to switch to mania (Wilens et al 2003; Fava et al 
2005).
Common side effects are headache, nausea, dry mouth, 
insomnia, sweating, and constipation. An important possible 
adverse event is the emergence of seizures. Bupropion is 
associated with statistically signiﬁ  cantly less sexual dys-
function than SSRIs, including orgasmic dysfunction (Fava 
et al 2005).
Results of multicenter, randomized, double blind, pla-
cebo-controlled trial demonstrated that bupropion XL was 
signiﬁ  cantly more effective than placebo and improved 
ADHD symptoms in adults (Wilens et al 2005). Bupropion 
is not yet FDA approved for treatment of ADHD.
Tricyclic antidepressants
Tricyclic antidepressants improve mood and decrease hyper-
activity, but do not improve concentration and cognitive tasks 
(Weiss and Hechtman 1993). Desipramine has fewer side 
effects than other tricyclics and therefore it has been the most 
studied tricyclic antidepressant in the treatment of ADHD. 
Desipramine is an active metabolite of tricyclic antidepres-
sant, imipramine. Desipramine selectively inhibits reuptake 
of norepinephrine at the presynaptic transporter, resulting in 
increased availability of norepinephrine.
Desipramine has shown efﬁ  cacy in the treatment of 
ADHD. Typical daily dose is 1.5–3 mg/kg (Weiss and 
Hechtman 1993). Therapy should start with a dose of 50 mg 
and every 7 days this dose can be increased by 50 mg until 
the optimal beneﬁ  t are seen. The maximum dose is 300 mg 
per day (CADDRA 2006).
Research data have shown that desipramine is effective in 
the treatment of ADHD in adults (Spencer et al 2004), but it 
is less effective than stimulants. Side effects of desipramine 
are similar to side effects of other tricyclic antidepressants 
and include dry mouth, constipation, sweating, blurred 
vision, insomnia, decreased appetite, tachycardia, increased 
blood pressure, EKG changes (particularly prolonged QT 
interval), orthostatic hypotension, and drowsiness. Such 
adverse effects suggest possible cardiotoxic effects, and 
this limits the wider use of despiramine in the treatment of 
patients with ADHD.
Clonidine
Clonidin is α2-adrenergic receptor agonist that has effect on 
symptoms of hyperactivity and impulsivity, but not those of 
inattention. Clonidine is considered as a second-line agent in 
the treatment of ADHD and may be useful in some patients 
with comorbidity, particularly in the treatment of patients 
with comorbid ADHD and Tourette’s syndrome and other 
tic disorders (Robertson 2006; Wilens 2006). Common side 
effects are dry mouth, sedation, drowsiness, dizziness, and 
constipation (Powers 2000).
Guanfacine
Guanfacine is a direct agonist of the α-2a subtype of norepi-
nephrine receptors, which are particularly numerous in the 
prefrontal cortex and the locus ceruleus. Guanfacine actions 
on the α-2a receptors of the locus ceruleus could modulate 
locus ceruleus discharge rates and result in improved atten-
tional abilities. Attention also could be improved indirectly 
via locus ceruleus effects on central dopaminergic neuron 
(Taylor and Russo 2001).
Guanfacine is less sedating and has a longer duration of 
action than clonidine (Lopez, 2006). Guanfacine is effective 
treatment for symptoms of ADHD. It is especially helpful 
for patients with liability for abuse of stimulants. Guanfacine 
is safe and well tolerated in children and adults with ADHD 
(Biederman 2006).
Modaﬁ  nil
Modaﬁ  nil is an agent that promotes wakefulness and is 
approved by the FDA for treatment of narcolepsy. Accurate 
mechanism of its action is not known. Modaﬁ  nil has several 
effects on the brain. It is presumed that Modaﬁ  nil’s effects 
are mediated by activation of noradrenergic α1 receptors by 
blocking the reuptake of dopamine in the cerebral cortex and 
caudate. Modaﬁ  nil also inhibits γ-aminobutyric acid neurons 
in the ventrolateral preoptic nucleus, which normally inhibits Neuropsychiatric Disease and Treatment 2008:4(2) 398
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noradrenergic neurons in locus ceruleus and histamine 
neurons in tuberomammillary nucleus. In this way modaﬁ  nil 
activates noradrenergic neurons and histamine neurons with 
resulting “wakeful state”. Modaﬁ  nil increases release of 
glutamate in the hippocampus and in the thalamus which 
results in increasing of vigilance. Finally, Modaﬁ  nil activates 
hypocretin neurons in the lateral hypothalamus. Hypocretin 
peptides stimulate the release of histamine; thus again causes 
arousal (Wilens 2006; Ballon at al 2006).
Modaﬁ  nil is a well-tolerated drug with mild side effects 
and with low propensity for abuse. Most common side effects 
are insomnia, headache and decreased appetite. Modaﬁ  nil 
can be administered once daily (Turner 2006). Modaﬁ  nil 
ﬁ  lm-coated tablets present a new formulation that is admin-
istered once daily. Placebo-controlled studies in children and 
adolescents have shown that this formulation is effective in 
the full spectrum of ADHD symptoms (Biederman 2006). 
In order to determine the role of modaﬁ  nil in the treatment 
of ADHD, there is a need for large, long-term comparison 
studies of modaﬁ  nil and long- and short-acting stimulants 
(Lindsay et al 2006).
Treatment of ADHD patients with 
comorbid diagnoses
Approximately 75% of adults with ADHD have at least one 
comorbid condition. Implications of comorbidity for the treat-
ment are signiﬁ  cant because the treatment protocols should 
involve treatment strategies for both disorders. Some comorbid 
disorders may adversely inﬂ  uence the response of these adults 
to medication for ADHD (Barkley and Gordon 2002).
As a general principle the most severe and impairing 
condition should be treated ﬁ  rst with the most effective 
available medication. Once some improvement is noticed 
treatment of other condition can proceed using the most 
effective medication if possible.
ADHD and depression
ADHD and major depressive disorders are among the most 
common psychiatric disorders occurring in adulthood, and 
comorbidity rates between them are high.
According to the US National Comorbidity Survey, 
the prevalence rate of ADHD among adults with major 
depression is 9.4%, whereas in patients with dysthymia the 
prevalence rate of ADHD is 22.6% (Kessler et al 2006). 
Comorbidity between ADHD and major depression is clini-
cally signiﬁ  cant, although the clinical presentation of depres-
sion is not different among those with ADHD compared to 
those without ADHD.
Generally, if depression is severe, it needs to be treated 
prior to treating ADHD. The best strategy for treating ADHD 
with comorbid depression is a combination of stimulant and 
antidepressant medications. SSRIs combined with stimulants 
can be safe and effective, while the chance for potential drug 
interactions is small (Nutt et al 2006; Prince and Wilens 
2000). Combination therapy, which would involve stimulants 
with serotonergic-noradrenergic reuptake inhibitors (SNRIs), 
can also be successful, but in such combination it is very 
important to monitor sympathomimetic side effects, which 
are present with both classes of drugs. Combining atomox-
etine with SSRIs can be difﬁ  cult since both are metabolized 
via the cytochrome P450 enzyme system (2D6).
In patients with manic episode or bipolar disorder and 
ADHD, therapy with mood stabilizers and/or atypical anti-
psychotics is indicated before the treatment with stimulants. 
Stimulants carry a potential risk of worsening or triggering 
bipolar symptoms (Nutt et al 2006) and accordingly bupro-
pion could be a ﬁ  rst choice medication for this comorbidity. 
An open trial of bupropion for the treatment of adult patients 
with ADHD and comorbid bipolar disorder suggested that 
sustained-release bupropion may be effective in treating 
ADHD and it is not associated with signiﬁ  cant activation 
of mania. Most bipolar patients in this research study were 
diagnosed with bipolar II disorder (Wilens et al 2003; Fava 
et al 2005).
ADHD and anxiety disorders
Children and adults with ADHD have much higher rates of 
anxiety disorders than match normal controls (Biederman 
2004). Clinical and epidemiological studies demonstrated 
that lifetime prevalence of anxiety disorders in adult patients 
with ADHD is 40%–60% (Sobansi 2006). In case of comor-
bidity of ADHD with anxiety disorders stimulant medications 
should be the ﬁ  rst therapeutic intervention. Anxiety symp-
toms generally do not worsen on stimulant medication. A 
second treatment intervention would be speciﬁ  c therapy for 
anxiety disorders either with SSRIs or cognitive-behavioral 
therapy (CBT). The most beneﬁ  cial treatment option is 
combined therapy.
Initial studies evaluating the response to stimulants in 
patients with ADHD and anxiety suggested that they had a 
reduced response to stimulants. However, more recent studies 
have not supported decreased stimulant response in anxious 
ADHD patients (Hechtman et al 2005).
In a study of the treatment of adults with ADHD and 
comorbid anxiety and depressive disorders, Hechtman 
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Treatment of adult ADHD
a monotherapy, dextroamphetamine as a monotherapy 
and the combination of both medications. Results 
demonstrated that ADHD symptoms markedly improved 
with dextroamphetamine. Anxiety and depressive symptoms 
were improved with paroxetine.
Patients who received both dextroamphetamine and 
paroxetine improved in both ADHD and anxiety/depressive 
symptoms but not to the same extent as with monotherapy 
and they had more severe adverse events (Hechtman et al 
2003; Weiss et al 2006).
ADHD and substance use disorders
Adults with ADHD and substance use disorders have earlier 
onset of substance abuse in comparison with adults without 
ADHD. Nine to 30% of adults with ADHD have problems 
with drug abuse or dependence (Wilens 2004a).
In the treatment of patients with ADHD and substance use 
disorders, it is recommended to ﬁ  rst treat substance abuse (Nutt 
et al 2006), although ADHD medication can be initiated along 
with the treatment for substance use disorder. Atomoxetine, 
bupropion, tricyclic antidepressants should be contemplated 
as a ﬁ  rst line of treatment for these patients (Wilens 2004b). 
Active substance abuse is a contraindication for stimulant 
medications. However, if nonstimulant medications are inef-
fective, considering a stimulant trial is warranted for patients 
who are in a stable substance abuse remission. Stimulants are 
thus considered second-line agents for adolescents and adults 
with ADHD and substance use disorders (Wilens 2004b). 
Extended-release or longer-acting stimulants with lower abuse 
liability and diversion potential are preferable (Wilens 2004a). 
Treatment with stimulants needs to be performed with special 
caution and should be carefully monitored.
There has been speculation that a high rate of substance 
abuse among the adults with ADHD is caused by the use of 
stimulant medications. Research studies do not support the 
claim that stimulant treatments add to the risk of substance 
abuse in the patients with ADHD (Wilens 2004b). Finally, it 
is important to keep in mind that stimulant treatment gener-
ally reduces the risk for substance use disorder.
Psychosocial treatment
Every psychotherapy approach for adult ADHD patients 
needs to address speciﬁ  c problems they face. These prob-
lems are poor time management and organizational skills, 
impulsivness, insufﬁ  cient problem solving skills, academic 
and social failures, problems with self-esteem, difﬁ  culties 
maintaining relationships, temper outbursts, potential antiso-
cial behavior, etc. In order to better clarify all of the problems 
that may affect adults with ADHD, it is recommended that 
every psychotherapy treatment contain a psychoeducational 
component.
Psychoeducation involves teaching patients about their 
disorder, including how ADHD affects different areas of 
their lives and relationships, how to recognize symptoms of 
ADHD, and how to treat it. Psychoeducation is important 
for treatment compliance and long-term adherence, and it is 
needed for patients as well as their signiﬁ  cant others. Teach-
ing patients about ADHD and its impact on their lives and 
daily functioning may improve the self-esteem of the patients, 
who are frequently regarded as lazy or less intelligent.
Psychosocial treatment should be evidence based. Psy-
chotherapeutic modalities, which may fulﬁ  ll the speciﬁ  c 
needs of adult ADHD patients, include individual and group 
cognitive-behavioral therapy, family therapy, and other 
interventions.
Cognitive-behavioral therapy
Cognitive-behavioral therapy (CBT) is suitable for adults 
with ADHD because it is a collaborative model with a good 
structure. It was designed to promote self-controlled behavior 
by enhancing self mediation and control strategies (Weiss and 
Hechtman 1993). Initial trials were based on the conceptual-
ization that impulsive patients with ADHD should be taught 
to talk to themselves as means of developing self-control.
An important question is what is the mechanism of action 
of CBT in patients with ADHD. In an attempt to explain 
the therapeutic effects of different treatments, Rapport 
and colleagues (Rapport et al 2001) formed the conceptual 
model of ADHD. According to this model, stimulants have 
a direct impact on the neurobiological substrate of ADHD, 
whereas CBT affects the core psychological (ie, behav-
ioral and cognitive) features. Other nonspeciﬁ  c and more 
supportive psychosocial treatments inﬂ  uence peripheral 
or secondary features of ADHD, such as job or academic 
underachievement, inadequate social skills, and disturbed 
family relationships.
Rostain and colleagues have a different point of view. 
They hypothesized that patients’ symptoms improve in psy-
chotherapy because CBT effectively treats their comorbid 
conditions rather than the core symptoms of ADHD (Rostain 
et al 2006).
Cognitive-behavioral therapy for ADHD can be adminis-
tered in individual or group format. Group format has some 
advantages. Group therapy provides the opportunities to meet 
people with similar problems, share information, and learn 
how others cope with their difﬁ  culties (Young 2002).Neuropsychiatric Disease and Treatment 2008:4(2) 400
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Literature on the efﬁ  cacy of CBT in adults with ADHD 
is sparse. One early retrospective study on the use of CBT 
in the treatment of adults with ADHD was conducted by 
Wilens and colleagues (Wilens et al 1999). Patients were 
treated with an adapted form of Beck’s cognitive therapy 
with a focus on dysfunctional cognitive schemas and 
cognitive restructuring. Treatment consisted of 36 sessions 
and, according to a chart review of the symptoms of 26 
patients, produced improvements not only in the symptoms 
of ADHD but also on measures of depression and ratings 
of overall functioning. There are two important notable 
limitations of this study. There was no control group and 
the treatment evaluation was done retrospectively via 
chart review.
Stevenson and colleagues (Stevenson et al 2002) devel-
oped a cognitive remediation program (CRP) for adults with 
ADHD, oriented to reduce the impact of cognitive impair-
ments. The CRP was designed for a small therapy group and 
consists of three main components: eight group sessions, 
once weekly; support people who acted as coaches; and 
workbooks with exercises. Treatment signiﬁ  cantly improved 
ADHD symptoms, organizational skills, and self-esteem. The 
limitations of this study are its small sample size (N = 22) 
and the fact that the assessment of treatment outcomes was 
done only by self-report ratings.
Rostain and colleagues (Rostain et al 2006) evaluated a 
combined treatment for 43 adults with ADHD, using con-
current pharmacotherapy and CBT. The CBT consisted of 
16 individual psychotherapy sessions over the course of six 
months. All patients received mixed salts of amphetamine. 
The results demonstrated that the combination of pharma-
cotherapy and CBT is effective in the treatment of a wide 
range of ADHD-related symptoms, symptoms of anxiety and 
depression, and overall functioning.
Hesslinger and colleagues (2002) evaluated the efﬁ  cacy 
of a structured skill-training program in the treatment of 
adults with ADHD. The therapy was based on the principles 
of dialectical behavior therapy, modiﬁ  ed to suit the speciﬁ  c 
needs of adults with ADHD. In addition to components 
of CBT, the treatment included mindfulness. Results of 
this study showed improvement in ADHD symptoms and 
an overall reduction of symptomatology, as measured by 
psychometric scales. However, this study had many limita-
tions, including a very small number of patients (N = 7) and 
the continuation of medication treatment in some patients 
(Hesslinger et al 2002).
A model of cognitive-behavioral therapy for adult ADHD 
that was developed by Safren (2006) involves six modules. 
Three of them are “core modules” and another three are 
optional modules. Core modules are organizing and planning, 
distractibility, and cognitive restructuring. Optional modules 
are procrastination, anger and frustration management, and 
communication skills. Safren and colleagues evaluated the 
efﬁ  cacy of the cognitive-behavioral therapy for adults with 
ADHD who have not fully responded to medications alone. 
Among 31 patients who received CBT 56% were treatment 
responders compared to only 13% non-responders. Authors 
concluded that CBT might be a useful component in the 
treatment for adults with ADHD who do not fully respond to 
medications alone (Safren et al 2004; Safren 2006). Limita-
tions of this study include no randomization, no control or 
comparison group, small sample size, and no adequate control 
of pharmacotherapy.
We developed a cognitive behavioral therapy program 
for adults with ADHD which included the following 
twelve modules: psychoeducation (ADHD symptoms, the 
neurobiology of ADHD and pharmacological treatment), 
organizational skills training, time management, anger 
management, stress inoculation training, cognitive 
reframing, self-control and self-esteem, and relationship 
management (Galina et al unpublished). Treatment is 
administered in a group format with once weekly group 
sessions. Intensive therapy lasts 12-weeks and then patients 
receive a monthly booster session for three months. 
Our CBT program includes coaching. Coaches, who are 
psychologists or student of psychology and medicine who 
have received special training in coaching activities for 
cognitive-behavioral therapy. Coaches contact patients 
by phone twice a week and help them implement CBT 
strategies outside of the session. This ongoing study will 
explore the efﬁ  cacy of CBT in adult ADHD.
Besides the treatment of ADHD, cognitive-behavioral 
therapy could be very useful for the treatment of comorbid 
states as well. Cognitive-behavioral therapy may be a 
particularly effective therapy for adults with ADHD and 
substance use disorders, especially cognitive therapy 
interventions and an integrated relapse prevention program 
(Wilens 2004). For comorbid depression and anxiety 
disorders, psychosocial interventions particularly a 
combination of cognitive behavioral therapy and medication, 
are also very effective.
Family and marital therapy/
counseling
Adults with ADHD have a signiﬁ  cantly less successful 
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without ADHD. They also have a higher incidence of 
separation and divorce than normal control. Marital 
problems are common complaints of adults with ADHD 
seeking treatment (Eakin et al 2004). Spouses who do 
not have ADHD usually complain that their partner is 
unreliable, messy, disorganized, forgetful, a poor listener, 
etc. Spouses also feel overburdened because they have to 
take care of all things in the family. Likewise, spouses 
of ADHD patients think that their spouse does not 
make a sufﬁ  cient effort in order to change his/her behavior. 
Therefore, education about the disorder needs to involve 
the spouse of ADHD patients as well. Both, the patient 
and the spouse, beneﬁ  t from learning about ADHD and its 
consequences on the patient’s behavior and functioning. 
Gaining a better understanding of ADHD and realizing 
that many of the patient’s behaviors are not a result of a 
lack of caring or a willful misconduct, may contribute to 
a reduction of blaming each other (Murphy 2005). Family 
therapists focus on how patterns of interaction maintain 
the family or marital problems. Moving the focus from 
“identiﬁ  ed patient” to the interaction between spouses or 
family members can be useful. Everyone within the family 
and each spouse has an important role in rebuilding the 
relationship.
Summary
ADHD is prevalent neurobiological condition, affecting 4.4% 
of the general population. It is accompanied by high rates 
of comorbidity (depression, anxiety, substance abuse) and 
signiﬁ  cant social, emotional, and occupational impairments, 
which affect the patients and their families.
The article brieﬂ  y reviews prevalence, diagnosis, differ-
ential diagnosis, and comorbidity of ADHD in adulthood. 
However, the major focus of the paper is the treatment of 
adults with ADHD. The strengths and limitation of medi-
cation (stimulant and nonstimulant) treatment as well as 
psychosocial treatment, particularly cognitive behavioral 
therapy are summarized.
For each medication or class of medication key aspects 
such as possible mechanism of action, titration schedule with 
starting and maximum dosages, therapeutic effects and side 
effects are outlined. Generally long acting stimulants are the 
most effective treatment approach. Medication treatment for 
patients with ADHD and various comorbid conditions, eg, 
depression, anxiety, bipolar disorder and substance abuse 
are also described.
Finally, the efﬁ  cacy of psychosocial treatment, particularly 
cognitive behavioral therapy is addressed. Combined 
medication and psychosocial treatment approach are 
recommended as an effective treatment for most patients 
with ADHD.
Future research directions
Even though the research literature in ADHD is vast and 
growing much remains to be done.
1.    Etiology and Pathogenesis: The etiology and patho-
genesis of ADHD is still in its infancy. Genetic and 
neurobiology research using modern technology will 
hopefully clarify these issues in the future.
2.   Epidemiology of Adult ADHD: There is one large study 
conducted in the U.S. by Kessler et al 2006. Epidemio-
logical studies of adults ADHD in other parts of the 
world are totally lacking.
3.    Appropriate Diagnostic Criteria: DSM-IV and ICD-10 
diagnostic criteria for adults with ADHD are derived 
from child studies or clinical presentation of children 
and are therefore not appropriate for adults. Diagnostic 
ﬁ  eld trials of adults need to be carried out to arrive at 
appropriate criteria for diagnosing adults with ADHD. 
Currently its unclear how adults diagnosed as children 
with ADHD differ from those who are newly diagnosed 
in adulthood. We know little about the impairment of 
adults who do not currently meet all diagnostic criteria 
and have a “subclinical diagnosis”.
4.    Comorbidity: We need to learn better ways to decrease 
comorbidity in adults with ADHD and to treat it more 
effectively when it does occur.
5.    Duration of Treatment and Follow up: More research is 
needed to determine optimal duration of treatment and 
optimal frequency, type and lenght of follow up. It’s 
clear that short term treatment is effective, but we need 
to determine how to translate this efﬁ  cacy into long term 
positive outcome for patients and their families.
In summary there is still much to be done in the area of 
ADHD in adulthood.
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